Leerink Partnrs Issues Optimistic Estimate for TENX Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Leerink Partnrs increased their Q2 2025 earnings per share estimates for Tenax Therapeutics in a research note issued to investors on Thursday, May 15th. Leerink Partnrs analyst D. Risinger now anticipates that the specialty pharmaceutical company will post earnings per share of ($1.07) for the quarter, up from their prior forecast of ($1.12). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q3 2025 earnings at ($3.37) EPS, Q4 2025 earnings at ($4.53) EPS, FY2026 earnings at ($6.07) EPS, FY2027 earnings at ($5.12) EPS, FY2028 earnings at ($3.32) EPS and FY2029 earnings at ($1.31) EPS.

Other equities research analysts also recently issued research reports about the company. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. StockNews.com began coverage on Tenax Therapeutics in a research note on Friday, May 16th. They issued a “sell” rating for the company. Leerink Partners set a $20.00 price target on Tenax Therapeutics in a research note on Monday, March 10th. Finally, Guggenheim reiterated a “buy” rating and issued a $15.00 price target on shares of Tenax Therapeutics in a research note on Thursday, May 15th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $6.00 on Monday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89. The stock’s 50-day moving average is $5.85 and its 200 day moving average is $5.93. The company has a market cap of $24.89 million, a P/E ratio of -2.42 and a beta of 1.92.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings data on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. ADAR1 Capital Management LLC increased its position in shares of Tenax Therapeutics by 98.1% in the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after buying an additional 34,048 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Tenax Therapeutics in the fourth quarter worth approximately $84,000. Millennium Management LLC acquired a new stake in shares of Tenax Therapeutics in the fourth quarter worth approximately $166,000. Janus Henderson Group PLC acquired a new position in Tenax Therapeutics during the fourth quarter worth $1,026,000. Finally, Geode Capital Management LLC raised its stake in Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares during the period. 1.67% of the stock is owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.